Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)
Authors' conclusion
PDAS1 is a reliable and useful tool for evaluating both disease activity and the functional state of RA patients, particularly from the perspective of PROs.
Study context
- Population
- RA patients in the National Database of Rheumatic Diseases in Japan (NinJa), 2022 version
- Participants
- 11,983 patients
- Exposure
- PDAS1 vs other clinical measures; IL-6 inhibitors vs TNF inhibitors
- Outcome
- PDAS1 relationship with other clinical measures
Methodological detailsregistry-based, propensity-score matched comparison
- Registry-based
- Propensity-score matched comparison
Main finding
As reported in the abstract
Correlation of PDAS1 with DAS28(ESR), R (P < 2.2 × 1016)
0.89
Patients achieving PDAS1-defined remission
71.8%
Correlation of PDAS1 with serum RF titres, R (P < 0.001)
0.25
Observational data: associations, not effects.
Further findings
PDAS1, propensity score (PS)-matched comparison by DMARD type
- PDAS1 lower with IL-6 inhibitors vs TNF inhibitors, reflecting lower PGA
- Propensity score matched
Original publication
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry). Rheumatology (Oxford). Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →